Search

for
Search:

GlossaryRitlecitinib

investigational drug targeting enzymes involved in autoimmune hair loss

Ritlecitinib is an investigational drug that targets specific enzymes known as Janus kinases (JAKs) and TEC family kinases, which are involved in the immune response. It is being studied for its potential to treat autoimmune conditions like alopecia areata, where the immune system mistakenly attacks hair follicles, leading to hair loss.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 248 results

Hydrogel Forming Microneedles Loaded With VEGF and Ritlecitinib/Polyhydroxyalkanoates Nanoparticles for Mini-Invasive Androgenetic Alopecia Treatment

research Hydrogel Forming Microneedles Loaded With VEGF and Ritlecitinib/Polyhydroxyalkanoates Nanoparticles for Mini-Invasive Androgenetic Alopecia Treatment

April 2024 in “Bioactive materials”

New microneedle treatment with growth factors and a hair loss drug shows better and faster hair growth results than current treatments.

research The FDA Approves Litfulo® (Ritlecitinib) for the Treatment of Severe Alopecia Areata in Adolescents and Adults

September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)”

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

research Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers

36 citations , December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

research Research Progress in the Treatment of Non-Scarring Alopecia: Mechanism and Treatment

May 2025 in “Frontiers in Pharmacology”

New treatments are needed for non-scarring alopecia due to current limitations.

Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway

research Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway

January 2023 in “Indian Dermatology Online Journal”

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

View more "ritlecitinib" in research →

Community Join

4 / 4 results

community How do we only have two treatments to combat hair loss at this point in time?

in Chat 211 upvotes 2 years ago

The post discusses frustration over the limited and not always effective treatments for hair loss, mainly Minoxidil and Finasteride. The conversation includes mentions of potential new treatments like GT20029, HMI-115, CosmeRNA, KX-826, and microneedling, but also highlights the challenges of funding and prioritizing research in this area.

community Article of all potential future cures

in Treatment 25 upvotes 10 months ago

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

community Anyone else taking Litfulo (ritlecitinib) to treat their alopecia?

in Treatment 6 upvotes 2 years ago

A user diagnosed with Alopecia Areata started using Litfulo (ritlecitinib), kenalog shots, and mometasone furoate 0.1%. They shaved their head and are seeking others' experiences with Litfulo.

community Update July 2025] Most Promising Hair Loss Treatments in Clinical Trials

in Research/Science 269 upvotes 8 months ago

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.